Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bristol-Myers Squibb Company

https://www.bms.com/

Latest From Bristol-Myers Squibb Company

Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas

Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.

Deals Business Strategies

Roche Hit By Surprising Tecentriq Miss In TNBC

Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.

Clinical Trials Companies

Trio Face 11 Year Wait On Eliquis As US Patents Upheld

Three ANDA sponsors – HEC’s Sunshine Lake, Sigmapharm and Unichem – for generic versions of Eliquis had elected to take their Hatch-Waxman case to trial but were soundly beaten by originator’s Bristol-Myers Squibb and Pfizer. A launch in 2031 could now be their best, and only, option.

Legal Issues Intellectual Property

GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning

US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.

Approvals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Adnexus Therapeutics, Inc.
    • Allied-Bristol Life Sciences, LLC
    • Amira Pharmaceuticals, Inc.
    • Amylin Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Bristol-Myers Company
    • Bristol-Myers K.K.
    • Bristol-Myers Squibb
    • Cardioxyl Pharmaceuticals
    • Celgene Corporation
    • Cormorant Pharmaceuticals
    • Delinia, Inc.
    • EngMab AG
    • Flexus Biosciences, Inc.
    • Gloucester Pharmaceuticals, Inc.
    • ißeCa Therapeutics
    • IFM Therapeutics
    • Impact Biomedicines, Inc.
    • Inhibitex, Inc.
    • iPierian Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Kosan
    • Medarex, Inc.
    • Padlock Therapeutics, Inc.
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • Westwood-Squibb Pharmaceuticals
    • X-BODY, Inc.
    • ZymoGenetics, Inc.
UsernamePublicRestriction

Register